Pier 88 Investment Partners’s AbCellera Biologics ABCL Stock Holding History

Pier 88 Investment Partners’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$627K	Sell	79,900 -40,200	-33%	-$197K	0.15%	48
2026 Q1	$419K	Buy	120,100 +14,370	+14%	+$51.7K	0.11%	84
2025 Q4	$362K	Sell	105,730 -3,140	-3%	-$14K	0.08%	101
2025 Q3	$548K	Sell	108,870 -135,310	-55%	-$596K	0.1%	88
2025 Q2	$838K	Buy	244,180 +390	+0.2%	+$971	0.16%	58
2025 Q1	$544K	Buy	243,790 +6,890	+3%	+$19.8K	0.1%	83
2024 Q4	$694K	Buy	236,900 +41,400	+21%	+$115K	0.14%	62
2024 Q3	$508K	Buy	195,500 +33,880	+21%	+$93.9K	0.11%	71
2024 Q2	$478K	Buy	161,620 +126,640	+362%	+$479K	0.11%	79
2024 Q1	$158K	Buy	+34,980	New	+$178K	0.04%	93

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Pier 88 Investment Partners's ABCL Position: Q2 2026 in Review

Pier 88 Investment Partners reduced its AbCellera Biologics (ABCL) stake by 33% in Q2 2026, selling an estimated $197K and leaving 79,900 shares worth $627K. The position accounts for 0.15% of the portfolio, ranked #48.

Pier 88 Investment Partners first reported a position in ABCL in Q1 2024 and has held it in 10 quarters since. The position peaked at $838K in Q2 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Pier 88 Investment Partners held 79,900 shares of AbCellera Biologics worth $627K as of Q2 2026.
Pier 88 Investment Partners sold 40,200 AbCellera Biologics shares in Q2 2026, an estimated $197K.
AbCellera Biologics made up 0.15% of Pier 88 Investment Partners's portfolio in Q2 2026, its #48 holding.
Pier 88 Investment Partners first reported a position in AbCellera Biologics in Q1 2024 and has held it in 10 quarters since.
Pier 88 Investment Partners's AbCellera Biologics position peaked at $838K in Q2 2025.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Pier 88 Investment Partners's 13F filing for Q2 2026, filed 4 Aug 2026.